Actively Recruiting
Haplo-HSCT for Myelofibrosis
Led by Peking University People's Hospital · Updated on 2025-05-14
39
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Myelofibrosis (MF) is a myeloproliferative neoplasm causing bone marrow failure and high risk of leukemia transformation. JAK2 inhibitors improve symptoms but do not cure MF. Allogeneic stem cell transplantation (allo-HSCT) is the only potential cure, though limited donor availability restricts access. Haploidentical transplantation shows promise but associated with higher graft failure and treatment related mortality. We recently developed a novel regimen of haplo-SCT for MF. This study aims to investigate this novel protocol in a prospective trial to improve MF outcomes.
CONDITIONS
Official Title
Haplo-HSCT for Myelofibrosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with myelofibrosis, including primary or secondary forms
- No matched sibling or unrelated donor available, but a haploidentical donor is available
- Signed informed consent to participate
You will not qualify if you...
- Active infection at the time of screening
- Very poor performance status (ECOG score greater than 2)
- Estimated survival less than 30 days
- Patient or family unable to cooperate with study procedures
- Considered unsuitable for the study after discussion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, China
Actively Recruiting
Research Team
S
Sun Yuqian
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here